A Phase 3 interventional study of bosentan in Pulmonary Hypertension, sponsored by Actelion. Completed. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-02-04.
Sponsored by Actelion (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies testing bosentan in Hypertension, Pulmonary — none open to participants now, none under way, none of them phase 3. Bosentan · Hypertension, Pulmonary.
Among the 19 studies testing bosentan in Hypertension, Pulmonary, this one is the 5th largest by enrollment, is one of 7 that started in 2006, is one of 8 in phase 3, and was the 7th registered.
1,092 studies on the registry are indexed under Hypertension, Pulmonary; 244 are open to participants now.
Browse Hypertension, Pulmonary studies →None of the 19 studies testing bosentan in Hypertension, Pulmonary is open now. The open studies under Hypertension, Pulmonary, anywhere →
Bosentan: first FDA approval 2001 (TRACLEER), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →
Of the 164 Hypertension, Pulmonary studies recruiting now, 99 (60%) set no upper age limit and 26 (16%) stop at 75 or younger; 39 take children under 18; 24 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 4 · Phase 3 9 · Phase 4 6
First in 2003; this study’s year is marked. 7 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 151 is above the median of 35 across 650 interventional studies indexed under Hypertension, Pulmonary.
Median enrollment 22 across the 19 interventional studies. Of the 16 that completed or were terminated, 4 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 19 have an industry lead sponsor. The 10 most frequent:
This study is registered under Actelion, one of the names counted as Johnson & Johnson. Under that name alone:
Actelion is the lead sponsor of 143 studies on the registry; 1 is open to participants now.
Of its 28 completed or terminated interventional studies of FDA-regulated products, 25 (89%) have results posted.
29 studies in Hypertension, Pulmonary by Johnson & Johnson: 1 open now, 2 under way, 2 of them phase 3. Of 27 finished, 13 (48%) have results posted.
Among the 29 studies in Hypertension, Pulmonary by Johnson & Johnson, this one is the 7th largest by enrollment of the 27 interventional ones that give a count, is one of 9 that started in 2006, is one of 13 in phase 3, and was the 10th registered.
Johnson & Johnson’s Hypertension, Pulmonary studies by the year they started, since 2003.
None of the studies under way reaches primary completion within a year.
Among the 19 studies testing bosentan in Hypertension, Pulmonary, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Johnson & Johnson’s 29 in Hypertension, Pulmonary:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The present trial investigates the long-term safety, tolerability and efficacy of bosentan in patients with inoperable CTEPH.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Open label bosentan treatment
Drug: bosentan
Oral bosentan * Initial dose: 62.5 mg twice a day (b.i.d.) for 4 weeks for all patients * Maintenance dose: 125 mg b.i.d. (62.5 mg b.i.d. if weight \< 40 kg)
Change From Baseline to All Assessed Time Points in 6-minute Walk Test (6MWT) Distance
Exercise capacity was assessed using the 6MWT. Area used for testing had to be a minimum of 30m in length and 2-3m in width, with 3m gradations. Areas were well ventilated with air temperature controlled. The test was administered at the same time of day and by the same tester throughout the study. The tester measured the distance walked by non-encouraged patients during the timed 6min period. If the test was stopped before 6 minutes, the main reason for stopping the test was recorded. The tester measured the distance walked by patients during the timed 6min period.
Time frame: Until discontinuation of study drug, up to 3.3 years
Change From Baseline to All Assessed Time Points in Borg Dyspnea Index
Maximal dyspnea during the walk test was assessed by the patient using the Borg dyspnea index. Immediately following each walk test, patients rated perceived maximal breathlessness during the walk test on a 12-point scale (0 \[nothing at all\], 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 \[maximum ever experienced\]).
Time frame: Until discontinuation of study drug, up to 3.3 years
Disease Severity - Number of Patients Showing Improvement by One Class or More in World Health Organisation (WHO) Functional Classification of Pulmonary Hypertension (PH)
Disease severity was assessed by WHO classification of PH criteria: Class I: no limitation of physical activity (PA). Ordinary PA: no undue dyspnea/fatigue, chest pain, near syncope. Class II: slight limitation of PA. Comfortable at rest. Ordinary PA: undue dyspnea/fatigue, chest pain, near syncope. Class III: marked limitation of PA. Comfortable at rest. Less than ordinary PA: undue dyspnea/fatigue, chest pain, near syncope. Class IV: inability to carry out PA without symptoms. Right heart failure. Dyspnea/fatigue may even have been present at rest. Discomfort increased by any PA.
Time frame: Until discontinuation of study drug, up to 3.3 years
Time to Clinical Worsening up to End-of-study
An event of clinical worsening was defined as death during the treatment period, a treatment-emergent adverse event that led to permanent discontinuation of study treatment and with outcome death, hospitalization due to worsening pulmonary hypertension, or lung transplantation. Patients are censored at 1 day after the end of treatment or at day of pulmonary endarterectomy if earlier.
Time frame: Until discontinuation of study drug, up to 3.3 years
Number of Patients With an Adverse Event(s) Leading to Premature Discontinuation of Study Medication
Time frame: Until discontinuation of study drug, up to 3.3 years
Number of Patients Experiencing a Serious Adverse Event(s) up to 28 Days After Study Medication Discontinuation
Time frame: 28 days after discontinuation of study drug, up to 3.3 years
Occurrence of Liver Function Test and Hemoglobin Abnormality
Number of patients with an increase in liver aminotransferases to \>3 times upper limit of normal (ULN) or a decrease in hemoglobin concentration to ≤10 g/dL
Time frame: Until discontinuation of study drug, up to 3.3 years
Patients were enrolled at 26 centers in 13 countries (Australia, Austria, Belgium, Canada, Czech Republic, France, Germany, Italy, The Netherlands, Poland, Spain, UK, and USA. The first patient started treatment on 26 January 2006 and the last patient received their last dose of study treatment on 23 February 2009.
| Milestone | Bosentan |
|---|---|
| Started | 151 |
| Completed | 104 |
| Not completed | 47 |
| Withdrew: Adverse event | 20 |
| Withdrew: Withdrawal of consent | 11 |
| Withdrew: Death | 9 |
| Withdrew: Lack of clinical improvement | 4 |
| Withdrew: Administrative | 2 |
| Withdrew: Treatment failure | 1 |
Exercise capacity was assessed using the 6MWT. Area used for testing had to be a minimum of 30m in length and 2-3m in width, with 3m gradations. Areas were well ventilated with air temperature controlled. The test was administered at the same time of day and by the same tester throughout the study. The tester measured the distance walked by non-encouraged patients during the timed 6min period. If the test was stopped before 6 minutes, the main reason for stopping the test was recorded. The tester measured the distance walked by patients during the timed 6min period.
| walk distance change from baseline (m) | Bosentan |
|---|---|
| month 6 | 8.4 ± 66.4 |
| month 12 | 18.2 ± 64.0 |
| month 18 | 17.7 ± 63.1 |
| month 24 | 20.2 ± 64.8 |
| end of the treatment period | 16.9 ± 69.4 |
Maximal dyspnea during the walk test was assessed by the patient using the Borg dyspnea index. Immediately following each walk test, patients rated perceived maximal breathlessness during the walk test on a 12-point scale (0 \[nothing at all\], 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 \[maximum ever experienced\]).
| Scores on a scale | Bosentan |
|---|---|
| month 6 | -0.5 ± 1.7 |
| month 12 | -0.4 ± 1.8 |
| month 18 | -0.1 ± 1.9 |
| month 24 | -0.1 ± 1.9 |
| end of the treatment period | -0.2 ± 2.1 |
Disease severity was assessed by WHO classification of PH criteria: Class I: no limitation of physical activity (PA). Ordinary PA: no undue dyspnea/fatigue, chest pain, near syncope. Class II: slight limitation of PA. Comfortable at rest. Ordinary PA: undue dyspnea/fatigue, chest pain, near syncope. Class III: marked limitation of PA. Comfortable at rest. Less than ordinary PA: undue dyspnea/fatigue, chest pain, near syncope. Class IV: inability to carry out PA without symptoms. Right heart failure. Dyspnea/fatigue may even have been present at rest. Discomfort increased by any PA.
| participants with improved WHO class | Bosentan |
|---|---|
| month 6 | 26 |
| month 12 | 30 |
| month 18 | 33 |
| month 24 | 33 |
| end of treatment period | 30 |
An event of clinical worsening was defined as death during the treatment period, a treatment-emergent adverse event that led to permanent discontinuation of study treatment and with outcome death, hospitalization due to worsening pulmonary hypertension, or lung transplantation. Patients are censored at 1 day after the end of treatment or at day of pulmonary endarterectomy if earlier.
| participants | Bosentan |
|---|---|
| month 6 (censored) | 11 |
| month 6 (events) | 8 |
| month 12 (censored) | 18 |
| month 12 (events) | 11 |
| month 18 (censored) | 25 |
| month 18 (events) | 15 |
| month 24 (censored) | 34 |
| month 24 (events)) | 19 |
| month 30 (censored) | 78 |
| month 30 (events) | 20 |
| month 36 (censored) | 122 |
| month 36 (events) | 21 |
| end of study (censored) | 130 |
| end of study (events) | 21 |
| participants | Bosentan |
|---|---|
| Number of Patients With an Adverse Event(s) Leading to Premature Discontinuation of Study Medication | 28 |
| participants | Bosentan |
|---|---|
| Number of Patients Experiencing a Serious Adverse Event(s) up to 28 Days After Study Medication Discontinuation | 51 |
Number of patients with an increase in liver aminotransferases to \>3 times upper limit of normal (ULN) or a decrease in hemoglobin concentration to ≤10 g/dL
| participants | Bosentan |
|---|---|
| Increase in liver function test | 27 |
| Decrease in hemoglobin | 9 |
Collected over Up to 28 days after the end of study drug. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Bosentan | — | 51/151 (33.8%) | 11/151 (7.3%) |
| Event | Bosentan |
|---|---|
| Right ventricular failureCardiac disorders | 11/151 |
| Pulmonary hypertensionRespiratory, thoracic and mediastinal disorders | 5/151 |
| Liver function test abnormalInvestigations | 5/151 |
| Cardiac failureCardiac disorders | 4/151 |
| Atrial fibrillationCardiac disorders | 3/151 |
| Atrial flutterCardiac disorders | 3/151 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 3/151 |
| Pulmonary arterial hypertensionRespiratory, thoracic and mediastinal disorders | 3/151 |
| AnaemiaBlood and lymphatic system disorders | 3/151 |
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 2/151 |
| Event | Bosentan |
|---|---|
| HEPATIC ENZYME INCREASEDInvestigations | 3/151 |
| LIVER FUNCTION TEST ABNORMALInvestigations | 3/151 |
| ANOREXIAMetabolism and nutrition disorders | 1/151 |
| ASPARTATE AMINOTRANSFERASE INCREASEDInvestigations | 1/151 |
| DYSPEPSIAGastrointestinal disorders | 1/151 |
| NASAL MUCOSAL DISORDERRespiratory, thoracic and mediastinal disorders | 1/151 |
| NAUSEAGastrointestinal disorders | 1/151 |
| PULMONARY HYPERTENSIONRespiratory, thoracic and mediastinal disorders | 1/151 |
| VOMITINGGastrointestinal disorders | 1/151 |
| Age, Continuous(years) | Bosentan |
|---|---|
| Mean | 63.1 ± 11.7 |
| Age, Customized(participants) | Bosentan |
|---|---|
| 25-81 years | 151 |
| Sex: Female, Male(Participants) | Bosentan |
|---|---|
| Female | 100 |
| Male | 51 |
| Region of Enrollment(participants) | Bosentan |
|---|---|
| Australia | 17 |
| Austria | 10 |
| Belgium | 8 |
| Canada | 6 |
| Czech Republic | 20 |
| France | 18 |
| Germany | 14 |
| Italy | 28 |
| Netherlands | 11 |
| Poland | 9 |
| Spain | 3 |
| United Kingdom | 2 |
| United States | 5 |
| Six-minute walk test (6MWT)(walk distance (m)) | Bosentan |
|---|---|
| Mean | 345.2 ± 93.4 |
| Borg dyspnea index(points on a scale) | Bosentan |
|---|---|
| Mean | 4.2 ± 2.2 |
| World Health Organisation (WHO) functional class(participants) | Bosentan |
|---|---|
| Class I | 3 |
| Class II | 41 |
| Class III | 91 |
| Class IV | 4 |
| Unassessed | 12 |
No study locations are listed for this record.
The record gives a start of Jan 2006, a primary completion of Feb 2009 and a completion of Apr 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2012, 3 years 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Bosentan